raloxifene hydrochloride has been researched along with trichostatin a in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balaguer, P; Bonnet, S; Cavaillès, V; Duong, V; Escande, A; Margueron, R; Vignon, F | 1 |
| Achilefu, S; Akers, W; Gu, Y; Li, H; Ma, Y; Tang, B; Tian, J; Tu, Z | 1 |
2 other study(ies) available for raloxifene hydrochloride and trichostatin a
| Article | Year |
|---|---|
Histone deacetylase inhibition and estrogen receptor alpha levels modulate the transcriptional activity of partial antiestrogens.
Topics: Breast Neoplasms; Enzyme Inhibitors; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogen Receptor Modulators; Female; Fulvestrant; Genes, Reporter; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Pyrrolidines; Raloxifene Hydrochloride; Response Elements; Tamoxifen; Thiophenes; Transcription, Genetic; Tumor Cells, Cultured | 2004 |
The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; CDC2 Protein Kinase; Cell Line, Tumor; Cell Proliferation; Cyclin B; Cyclin-Dependent Kinases; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Female; G1 Phase Cell Cycle Checkpoints; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Inhibitory Concentration 50; Raloxifene Hydrochloride; Receptors, Progesterone; Trefoil Factor-1; Tumor Suppressor Proteins | 2012 |